When Pfizer paid $11.6 billion for Array BioPharma in 2019, analysts praised the deal’s logic. Two years later, generic manufacturers […]

Ask anyone in pharma how long a drug patent lasts and they’ll say 20 years. The number is technically correct

When a buyer writes a $74 billion check for a drugmaker, they are not paying for the molecule. They are

Most pharmaceutical IP work gets framed as a pre-approval problem. File the composition patent during discovery, secure the use claims

The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how

Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to

The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other

A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot

The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least